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ABSTRACT 
This review is generally focussed on lipid-based excipients in solid oral formulations which increase its bioavailability. Several approaches have 
been used to deliver the drug efficiently in the body, and lipid excipients are one of the promising drug delivery systems which address challenges 
like solubility and bioavailability of water-soluble drugs. Lipids excipients can be tailored to meet a wide range of product requirements like disease 
indication, route of administration, stability, toxicity, and efficacy. This review discusses novel lipids like Compritol 888 ATO, Dynasan 114, and 
Precirol ATO 5 and how these can be employed for devicing efficient drug delivery models and thereby have used in cosmetic and pharmaceutical 
industries. 
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Lipids are essential for life, and the existence of cells specialized in 
fat storage has been conserved from flies and worms to humans. 
However, almost all cells maintain the capability to retain and 
accumulate lipids. Cellular mechanisms of lipid storage are 
relatively conserved from unicellular organisms, such as yeast, to 
complex organisms such as plants and mammals [1, 2]. An 
excipient (derived from words excipere to take out, receive) may 
be defined as any substances mixed with the active 
pharmaceutical ingredient to give it consistency or used as a 
vehicle for its administration. It is impossible for any active 
pharmaceutical ingredient to have properties that allow 
incorporation in a therapeutic product that meets all the 
mentioned requirements. Therefore, every therapeutic product is 
a combination of drug and excipients [3-5].  
The importance of lipid-based excipients in solid oral formulations 
has increased during the last decades, due to their outstanding 
benefits, such as providing modified release profiles or taste 
masking using solvent-free processing techniques [6]. Lipid-based 
excipients were first used in the 1960s for embedding drugs in a 
wax matrix in order to sustain drug release. In the more recent 
years, these excipients were successfully used in oral drug 
delivery systems to enhance the bioavailability of poorly aqueous 
soluble drugs and the novel lipids to control the release of easily 
soluble drug in the systemic circulation [7, 8]. Furthermore, taste 
masking and the improvement of swallow ability have been 
achieved with these excipients. Further reasons for the application 
of lipids in a formulation may be shelf life extension by protecting 
the drug from other ingredients or from environmental influences, 
the reduction of gastric irritation and the improvement of general 
attributes like flowability, lubrication performance, compressibility 
or mechanical resistance [9, 10]. 
Lipids 
Lipids are biological molecules characterized by limited solubility 
in water and solubility in non-polar organic solvents. Their 
intermolecular interactions are dominated by the hydrophobic 
effect and van der Waals interactions. Many lipids are, however, 
amphipathic molecules, which interact with other molecules and 
with aqueous solvents via hydrogen bonding and electrostatic 
interactions [11, 12]. Lipids are a diverse group of organic 
compounds found in plants, animal and micro-organisms. Lipids 
are non-polar compound and in-soluble in water but sometimes 
soluble in organic solvents. They comprise one of the three large 
classes of foods and, with proteins and carbohydrates, are 
components of all living cells [13-15].  
One of the most important functions of lipids is the role they play 
in cell membrane structure and metabolic processes, especially as 
cell membrane transport agents and precursors of signaling 
eicosanoids. These roles are becoming increasingly better 
understood and have allowed for the developments of a diverse 
number of applications of bioactive lipids both in the 
pharmaceutical and cosmetic fields.  
The major types of lipids that are present in the human body 
which plays major roles in metabolic processes are: 
triacylglycerols, free fatty acids, phospholipids, sphingolipids, bile 
salts, steroids and sterols, cholesterol, eicosanoids, and fat-soluble 
vitamins. Lipid modification strategies for the production of 
functional fats and oils include chemically or lipase-catalyzed 
interesterification or acidolysis reactions and genetic 
engineering of oilseed crops [16-19]. 
Classification of Lipids 
Lipids can be classified in many ways, due to their different 
composition, nature and origin. According to with Bloor's 
classification, lipids can be divided into simple lipids, compound 
lipids, and derived lipids. Individual characteristics are not 
discussed in this section because they are well known.  
Simple Lipids 
These are those compounds which belong to heterogeneous class of 
predominantly nonpolar compounds such as Lecithin and Cephalins. 
Compound Lipids 
These are esters of fatty acids with alcohols. Compounds molecules 
also contain additional functional groups such as a phosphate ion, 
simple sugar, amino acid, sulphate ion and oligopeptides. Examples 
are fatty acids, alcohols, monoglycerides and diglycerides, steroids, 
terpenes, carotenoids. 
Derived Lipids 
These are those substances which are derived from simple and 
compound lipids by hydrolysis. Derived lipids include fatty acids, 
alcohols, monoglycerides and diglycerides, steroids, terpenes, 
carotenoids. Steroids, terpenes and carotenoids are the most 
common derived lipids. Some of the most important lipids are 
shown in table 1, [20-25]. 
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Types of lipids Sources of lipids 
1. Simple 
lipids 
Triglycerides Oils Vegetable oils Almond, apricot, avocado, borage, canola, castor, coffee, corn, 
evening primrose, macadamia, olive, safflower, sesame etc. 
Animal oils Black Sea dogfish, emu, sardine, shark liver 
Fats Cocoa, coconut, palm, shea butter 
Waxes  Beeswax, jojoba, lanolin, spermaceti 
2. Compound 
lipids 
Phospholipids Phosphatidic acids 1,2-Dimyristoyl-sn-glycero-3-phosphate (DMPA)1,2-Dipalmitoyl-sn-glycero-3-
phosphate (DPPA) 1,2-Distearoyl-sn-glycero-3-phosphate (DSPA) 
Phosphatidyl glycerols 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) 1,2-Dipalmitoyl-sn-









 Phosphatidyl cholines 1,2-Dilauroyl-sn-glycero-3-phosphocholine (DLPC) 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 1,2-
Distearoyl-sn-glycero-3-phosphocholine (DSPC) 1,2-Dioleoyl-sn-glycero-3-
phosphocholine (DOPC)1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
Phosphatidyl serines  
Phosphatidyl inositols  
Phosphone analogs  
Sphingolipids Sphingophospholipids Sphingomyelin Egg sphingomyelin (ESM)N-palmitoyl sphingomyelin 
(C16SM) N-stearoyl sphingomielin (C18SM) 
Sphingoglycolipids Cerebrosides Gangliosides 
Glycolipids   
Sulfolipids Sulfogalactolipids  
3. Derived 
lipids 






Novel lipids are the new chemical entities, are designed using 
increasingly available receptor structural information. Such 
chemical entities formed are polycyclic and very hydrophobic. Novel 
lipids are poorly soluble and hence poor bioavailability; in this 
review, we will be discussing three novel lipids Compritol 888 ATO, 
Dynasan 114 and Precirol ATO 5 [26]. 
Compritol 888 ato 
Chemical Formula of compritol 888 ATO is C25H50O4 and its Non-
proprietary Name is Glycerol Dibehenate. Its chemical name is 2, 3-
dihydroxypropyl docosanoate: docosanoic acid or 2, 3-
dihydroxypropyl ester: glyceryl monobehenate [27]. 
Description  
Glyceryl behenate occurs as a fine white to off-white, free-flowing 
powder or hard waxy mass with a faint odor it is tasteless, non-
reactive with other formulation ingredients. The United States 
pharmacopeia national formulary (USP NF) describes glyceryl 
behenate as a mixture of glycerides of fatty acid, mainly behenic acid. 
Glyceryl behenate is a hydrophobic, non-swelling, wax material 
commonly used as a lubricant [28, 29]. Over the past decade, glyceryl 
behenate has been used for controlled release applications by direct 
compression and more recently by hot melt coating, melt granulation 
or pelletization or the formation of solid lipid nanoparticles. Due to its 
low density and controlled release nature, it is used for the 
development of gastric floating matrix tablets [30, 31]. Compritol 888 
ATO is a lipid excipient that is generally used in the cosmetic and 
pharmaceutical industry as a surfactant, emulsifying agent and 
viscosity-inducing agent in emulsions, creams and pharmaceutical 
product. Based on its chemical composition, Compritol 888 ATO is a 
blend of different esters of behenic acid with glycerol [32-34].  
Rationale for the use of compritol 888 ATO in novel drug 
delivery system 
Compritol 888 ATO has been extensively employed as a matrix-
forming agent in the preparation of different sustained-release 
tablets. It has also been investigated as a hot-melt coating agent for 
powders or granules for controlled release purposes [35, 36]. It has 
provided several noteworthy advantages over polymers as it is 
generally required in lesser amounts to achieve the desired effect 
and it does not crack during tablets compression. Moreover, 
Compritol 888 ATO has been examined for the preparation of pellets 
and orally disintegrating tablets. In addition, it has been used as a 
taste-masking agent to improve drugs palatability by concealing the 
bitter or unpleasant taste. Different researches have highlighted the 
applicability of Compritol 888 ATO in the preparation of aqueous 
colloidal dispersions such as solid lipid microparticles (SLMs), solid 
lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) 
for entrapment of lipophilic drugs [37-41]. Compared to 
homogenous glycerides, Compritol 888 ATO is superior in terms of 
drug entrapment ability due to its complex nature and less perfect 
orientation thus leaving more space for the drug to be loaded. Also, 
the long-chain length of behenic acid in Compritol 888 ATO 
enhances the intermolecular entrapment of the drug by interchain 
intercalation. Generally, lipid polymorphism occurs due to the 
difference in lateral packing possibilities of fatty acid chains in a 
particular organization of hydrocarbon chains. Lipids exist in 
different three-dimensional structures: unstable, metastable and the 
most stable modification [42-46]. Additional intermediate form 
exists between the most stable and metastable. Studying the 
polymorphic behavior of Compritol 888 ATO alone and within the 
SLNs and NLCs, it was found that the lattice arrangement of 
Compritol 888 ATO crystals generally comprises small amounts of 
the unstable polymorphic form that disappears after thermal stress 
[47]. In preparing SLNs, the stresses that might affect lipid stability 
are the initial melting procedure of the lipid to produce the hot pre-
emulsion and the subsequent high temperature and high pressure 
during the hot homogenization process. Partial formation of lower-
energy lipid modifications and reduction in crystallinity take place 
due to the transformation of Compritol 888 ATO into lipid 
nanoparticles. Also, the added surfactant during lipid nanoparticles 
preparation contributes to the lowering of the melting enthalpy of 
Compritol 888 ATO by distributing the melted lipid phase and 
distorting its crystallization [48-50]. It is postulated that the 
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surfactant may immobilize lipid molecules by interfacial contact and, 
consequently, avoid reorientation of less-ordered configurations 
into the more organized structural lattice. It is important to 
understand the thermal behavior of Compritol 888 ATO when used 
for hot-melt coating process since it undergoes melting and 
exposure to high temperatures [51, 52]. The thermal history, 
glycerides are exposed to, determines its crystal structure’s 
composition in terms of including hexagonal, orthorhombic and 
triclinic, each with different polymorphic transition temperatures 
and melting points. The polymorphic transitions affect drug release 
as better drug sustained release is related to the metastable 
polymorph [53, 54]. 
Composition and types of Compritol 
Compritol 888 ATO (glyceryl dibehenate or glyceryl behenate is a 
hydrophobic mixture of mono-(12-18% w/w), di-(45-54% w/w) 
and tri-(28-32% w/w) behenate of glycerol with melting point in 
range of 65-77 °C and with hydrophilic-lipophilic balance (HLB) of 2 
Compritol 888 ATO is prepared by the esterification of glycerin by 
behenic acid without the use of catalysts. The raw materials used in 
preparing are of vegetable origin and the esterified material is 
atomized by spray cooling [55]. 
According to the European pharmacopeia (EP), glyceryl dibehenate 
is a mixture of diacylglycerols (40-60%), together with 
monoacylglycerols (13-21%) and triacylglycerols (21-35%). 
However, the USP 32-NF 27 describes glyceryl behenate as a blend 
of glycerides of fatty acids, predominantly behenic acid and specifies 
that the content of 1-monoglycerides should range between 12 and 
18%. Glyceryl behenate can be identified using thin-layer 
chromatography and gas chromatography (GC) [56, 57].  
Compritols family, manufactured by Gattefosse and Ferromet corp. 
include Compritol HD5 ATO (behenoyl polyoxyl-8 glycerides NF) 
and Compritol E ATO (glyceryl behenate E471) [58]. 
 
 
Fig. 1: Structure of Compritol ATO 888 
 
Properties of Compritol ATO 888 
Compritol 888 ATO is a novel lipid and it is used for retardant 
release, the binding agent also etc. Properties of Compritol 888 ATO 
is shown in table 2. [59, 60]. 
 
Table 2: Property of Compritol ATO 888 
Melting point 65-77 °C 
HLB Value 2 
Molecular Weight 414.671g/mol 
Water Content (%) NMT 0.5% 
Acid Value ≤4 
Iodine Value ≤3 
Saponification Value 145-165 
Residue on Ignition ≤0.1% 
Heavy Metals ≤0.001% 
Free Glycerin ≤1% 
Soluble Chloroform and Dichloromethane 
Insoluble Ethanol, Hexane, Mineral Oil and Water 
 
Several studies have been conducted to examine the thermal 
behavior, crystallinity and possible interactions of the Compritol 
888 ATO and the drug that may impact its release. Compritol 888 
ATO has been mainly characterized using differential scanning 
calorimetry (DSC), X-ray powder diffraction (XRD) and Fourier 
transform infrared spectroscopy (FTIR) [61]. Generally, lipid 
polymorphism occurs due to the difference in lateral packing 
possibilities of fatty acid chains in a particular organization of 
hydrocarbon chains. The polymorphic form of Compritol 888 ATO 
either depends on parameters such as crystallization rate and 
temperature during production or storage. In slow crystallization 
rates, each glyceride crystallizes separately, producing a complex 
matrix containing different lamellar phases. On the contrary, a fast 
crystallization rate, or more produces a single lamellar phase [62, 63].  
Applications of Compritol 888 ATO 
Glyceryl behenate is used in cosmetics, foods and oral 
pharmaceutical formulations. In cosmetics, it is mainly used as a 
viscosity-increasing agent lipophilic matrix or coating for sustained 
released tablets and capsules. Viscosity-increasing agent in silicon 
gels (cosmetics). Viscosity-increasing agent in w/o or o/w emulsions 
(cosmetics). Glyceryl behenate is mainly used as a tablet and capsule 
lubricant and as a lipidic coating excipient. Used in the preparation 
of sustained-release tablets, as a matrix-forming agent for the 
controlled release of water-soluble drugs and as a lubricant in oral 
solid dosage formulations and can also be used as a hot-melt coating 
agent sprayed onto a powder [64-66]. 
 Modified-release dosage forms: Lipid nanoparticles have gained 
great interest during the past decade as they are more 
biocompatible and more stable compared to polymeric 
nanoparticles. Also, they offer high drug entrapment along with the 
feasibility of delivering both lipophilic and hydrophilic drugs. 
Compritol 888 ATO is considered one of the most applied and cited 
excipients in preparing SLNs and NLCs. Compritol 888 ATO-based 
nano-lipid carriers have been successfully utilized for ocular, oral, 
pulmonary, topical, transdermal and rectal delivery routes. 
Authors have selected it because of its favorable characteristics 
exemplified by its nonpolarity and lower cytotoxicity than other 
lipids [67].  
 Microparticles or spheres: Compritol 888 ATO used as core 
forming agent in preparing lipid-based porous microspheres. It 
has been shown that drug release from microspheres was 
dependent on Compritol 888 ATO and the increase in their 
concentration caused a reduction of drug release from the 
microspheres [68].  
 Compritol 888 ATO has been used in pellet lipophilic binders to 
prolong the release of drug from matrix pellets. Pellets exhibited 
excellent floating ability combined with sustained-release property 
due to the lipophilic nature of Compritol 888 ATO [69]. 
 Compritol 888 ATO has been successfully used by different 
research groups as a sustained-release matrix for tablets, to reduce 
the frequency of administration of drug [70]. 
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 In the hot-melt extrusion (HME) process, Compritol 888 ATO has 
been utilized for preparing extrudates with the immediate or 
sustained release [71]. 
Precirol ato 5 
Molecular Formula of precious ATO 5 is C37H76O7. Its Non-proprietary 
Name (EP) is Glycerol distearate, United States Food and Drug 
Administration (USFDA) Glyceryl palmitostearate and its Chemical 
Name is precirol ATO 5 is Glycerin palmitostearate, glycerol 
palmitostearate, 2-[(1-oxohexadecyl) oxy]-1, 3-propanediyl 
dioctadecanoate and 1, 2, 3 propane triol Glyceryl palmitostearate is 
a combination of mono-, di-, and triglycerides of C16 and C18 fatty 
acids, Glyceryl palmitostearate is available as a fine white powder 
with a faint odor [71, 72]. 
Composition and name of manufactures of Precirol ATO 5 
Glycerides are a family of excipients which have generated 
considerable interest in the preparation of oral dosage forms. Some 
glycerides such as Precirol ATO 5 (glyceryl palmitostearate) can be 
used for the preparation of sustained-release dosage forms. The 
esterification of glycerol by long-chain fatty acid gives them a 
pronounced hydrophobic character with a low HLB value of 2 [73, 74]. 
Glyceryl palmitostearate (Precirol ATO 5) is a mixture of mono-, di-, 
and triglycerides of C16 and C18 fatty acids, Glyceryl 
palmitostearate is used in oral solid-dosage pharmaceutical 
formulations as a lubricant [75]. 
Precirol ATO 5 is manufactured by Gattefosse corp. of France, 
Ferromet corp [76]. 
 
 
Fig. 2: Structure of Precirol ATO 5 
 
Properties of Precirol ATO 5 
Precirol ATO 5 is a novel lipid and its property is shown in table 3 [77].
 
Table 3: Property of Precirol ATO 5 
Melting point 52-55 °C 
HLB Value 2 
Molecular Weight 633.008g/mol 
Storage Condition 51-58 °C 
Boiling point 200 °C 
Physical Appearance White in Colour 
Soluble Chloroform and Dichloromethane 
Insoluble Ethanol, Mineral Oil, and Water 
 
Applications of Precirol ATO 5 
Glyceryl palmitostearate is widely used in oral solid-dosage 
pharmaceutical formulations as a lubricant. Tablet disintegration 
and time strengths depends on mixing time of glyceryl 
palmitostearate, as an increase in the blending time, increases 
disintegration time of tablets and also decreases the strength of 
tablet. It is used as a lipophilic matrix for the preparation of 
sustained-release product [78-80].  
Tablet formulations may be developed by granulation or any hot-melt 
technique, the former producing tablets that have a faster release 
profile. Release rate decreases with increased glyceryl palmitostearate 
content. Glyceryl palmitostearate is used to form microspheres, which 
may be used in capsules or compressed to form tablets,) pellets, 
coated beads and biodegradable gels. It is also used for taste-masking. 
It is used as a lipid in Solid Lipid Nanoparticles and other lipids nano 
and microparticulate colloidal delivery system [81, 82]. 
Function of Precirol ATO 5 
Biodegradable material is well used as a coating agent, gelling agent, 
release modifying agent, sustained-release agent, diluents in tablet 
capsule formulation, Lubricant, taste-masking agent. Lipid Matrix for 
Sustained Release, Coating for Protection and Taste Masking of Oral 
Solid Dosage forms in direct compression, Dry Granulation, Film 
Coating, Hot Melt Extrusion, Roller Compaction, Spheronization, 
Supercritical Fluid Extraction, Viscosity modification, Wet Granulation, 
Solid Lipid Nanoparticles, and Nano Lipid Carriers [83, 84]. 
Dynasan 114 
Molecular formula of dynasan 114 is C45H86O6. Its chemical names 
are Trimyristin; 555-45-3; Propane-1, 2, 3-triyl tritetradecanoate; 
Glycerol trimyristate; Myristin; Glyceryl trimyristate and its Synonyms 
are Tetradecanoic Acid 1, 1’, 1’’-(1, 2, 3-propanetriyl) Ester, Dynasan 
114-Glycerin Trimyristate, Glycerol Trimyristate, Glyceryl 
Trimyristate, Glyceryl Tritetradecanoate, Myristic Acid Triglyceride, 
Myristic Triglyceride, NSC 4062, Triglyceride MMM, Trimyristin, 
Trimyristoylglycerol, Tritetradecanoin, VP 114, Dynasan 
microcrystalline triglycerides are glycerine esters of selected 
saturated, even-numbered and unbranched fatty acids of plant origin. 
They are free from antioxidants and other Stabilizers [85, 86]. 
Composition and name of manufactures of Dynasan 114 
Trimyristin is an ester with the chemical formula C45H86O6. It is 
saturated fat, which is the triglyceride of myristic acid (C-14). 
Trimyristin is a white to yellowish-gray solid that is insoluble in 
water, but soluble in ethanol, benzene, chloroform, 
dichloromethane, and ether [84]. 
Dynasan 114 is manufactured by some of these limited private 
corporations: IOI Oleo limited, Toronto research chemical, Sasol 
Germany GmbH, Cremer care [87, 88]. 
 
 
Fig. 3: Structure of Dynasan 114 have been myristic acid (C-14) 
 
Properties of Dynasan 114 
Dynasan 114 is novel lipid and it is used for control release, pore 
form also and its property is shown on table 4 [89-92] 
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Table 4: Property of Dynasan 114 
Melting Point 55-58 °C 
HLB Value 3 
Molecular Weight 723.177g/mol 
Hydroxyl Value Max. 10 mg KOH/g 
Acid Value Max. 3 
Iodine Value Max. 1 
Saponification Value 229-238 
Unsaponifiable Matter Max. 0.5 
Soluble N-Hexane and Diethyl ether 
Insoluble Ethanol and water 
 
Applications of Dynasan 114 
Trimyristin is the triglyceride of myristic acid, which is found 
naturally in many vegetable fats and oils. Dynasan 114 
microcrystalline triglycerides are used in the cosmetic and 
pharmaceutical industries as adjuvants in the preparation of, In 
tablets as lubricants having a very low influence on disintegration, In 
suppositories, vaginal ovula and pharmaceutical/cosmetic sticks as 
crystallisation accelerators and seeding agents to improve the 
solidification process, In ointments, creams and lotions as body-
imparting and structure-forming components. 
Further, they can be used in cream and lotions as body imparting 
and structure forming. It is used in the pharmaceutical industry as a 
Biodegradable material, coating agent, gelling agent, release 
modifying agent, sustained-release agent, diluents in tablet and 
capsule formulation, Lubricant, taste-masking agent [93, 94]. 
ABBREVIATION 
DSC (Differential scanning calorimetry), EP (European 
pharmacopoeia), FTIR (Fourier Transform Infra-Red), GC (Gas 
Chromatography), HLB (Hydrophilic Lipophilic Balance), NLC 
(Nano-Structured lipid carriers), SLM (Solid Lipid Microparticles), 
SLN (Solid Lipid Nanoparticles), USFDA (United States Food and 
Drug Administration), USP-NF (United States Pharmacopoeia-
National Formulary), XRD (X-Ray Diffraction). 
CONCLUSION 
By increasing the bioavailability of numerous poorly soluble drugs 
along with formulations for physiologically well-tolerated class, the 
lipid excipients provide vast possibilities in this emerging 
technology. Understanding the physicochemical nature of the 
compound, alimentary canal and target receptor mechanisms, better 
and proficient drug delivery systems can be designed. 
Characterization, proper evaluation, and classification of these drug 
delivery systems are prerequisites to developing formulations and 
thereby boosting the pharmaceutical industry. 
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